Chapter

Israel's High‐Tech Catch‐Up Process: The Role of IPR and Other Policies

Meir Pugatch, Morris Teubal and Odeda Zlotnick

in Intellectual Property Rights, Development, and Catch-Up

Published in print April 2010 | ISBN: 9780199574759
Published online May 2010 | e-ISBN: 9780191722660 | DOI: http://dx.doi.org/10.1093/acprof:oso/9780199574759.003.0007
Israel's High‐Tech Catch‐Up Process: The Role of IPR and Other Policies

Show Summary Details

Preview

This chapter discusses the experience of Israel. At the time of its independence in 1948, its people came from different parts of the world, providing them with international orientation from the beginning. As a result, many of the businesses targeted foreign markets, mainly USA and Europe, and were more concerned with the intellectual property regime in these foreign countries than Israel's own. Together with public support for innovation and military‐related expenditure, some startup firms, mainly in information technologies, grew and succeeded in IPO (initial public offering) or selling themselves. Another successful case is Teva, now the largest generic drug producer. It benefited from the patent law amendment in 1967, which allowed local firms to copy patented drugs if the patent owners did not market them in Israel. This provision was dropped after TRIPS; however, Teva had accumulated process technologies by then.

Keywords: Israel; intellectual property; innovation; start‐up; IPO; generic; drug; patent; TRIPS; information technology

Chapter.  15879 words. 

Subjects: Innovation

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.